Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial

OBJECTIVE: To evaluate the efficacy and safety of dasiglucagon, a ready-to-use, next-generation glucagon analog in aqueous formulation for subcutaneous dosing, for treatment of severe hypoglycemia in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: This randomized, double-blind trial includ...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Care
Autors principals: Pieber, Thomas R., Aronson, Ronnie, Hövelmann, Ulrike, Willard, Julie, Plum-Mörschel, Leona, Knudsen, Kim M., Bandak, Benedikte, Tehranchi, Ramin
Format: Artigo
Idioma:Inglês
Publicat: American Diabetes Association 2021
Matèries:
Emerging Therapies: Drugs and Regimens
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247529/
https://ncbi.nlm.nih.gov/pubmed/35239971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc20-2995
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars